Accent Resources NL

ACS

Accent Resources NL engages in the exploration of mineral properties. The company is headquartered in Perth, Western Australia. The company went IPO on 2005-08-26. Its exploration is focused on the discovery and development of iron ore, base metal and precious metal deposits in its project areas in Western Australia. Its projects include Magnetite Range and Norseman. The Magnetite Range project is an advanced iron project, with greenfield gold potential, located approximately 260 kilometers (km) east southeast of Geraldton and immediately adjacent, and along strike of the operating Extension Hill iron ore mine. The Extension Hill project is also referred to as the Mt Gibson project. Magnetite Range project occurs west of the Great Northern Highway between Wubin and Paynes Find and consists of granted mining lease M59/166, granted exploration licenses E59/875 and 1732 and granted PL59/1952. The Norseman project, comprising five mining leases and eight prospecting licenses covering an area of approximately 338 hectares, is located five km south of Norseman in the Dundas Mineral Field.

Acrux Limited

ACR

Acrux Ltd. operates as a pooled development fund that invests in pharmaceutical businesses. The company is headquartered in Melbourne, Victoria. The company went IPO on 2004-09-29. The firm is engaged in developing and commercializing a pipeline of topically applied pharmaceutical products. Its products include Lidocaine and Prilocaine Cream, USP 2.5%/2.5%, Lenzetto, Evamist, Dapsone Gel, 5% and Testosterone Topical Solution, 30 mg / 1.5 ml. Lidocaine and Prilocaine Cream USP (a eutectic mixture of lidocaine 2.5% and prilocaine 2.5%) is indicated as a topical anesthetic for use on normal intact skin for local analgesia and genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anesthesia. Lenzetto (estradiol 1.53 mg/spray, transdermal spray, solution) is an estradiol spray for women which is used to treat moderate to severe hot flushes commonly associated with menopause. Testosterone Topical Solution is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.